Phospho-BTK (Y223) Antibody
-
中文名稱：磷酸化-BTK (Y223)兔多克隆抗體
-
貨號：CSB-PA000638
-
規格：￥1090
-
圖片：
-
Western Blot analysis of HeLa cells using Phospho-Btk (Y223) Polyclonal Antibody
-
-
其他：
產品詳情
-
Uniprot No.：
-
基因名：
-
別名：Agammaglobulinaemia tyrosine kinase antibody; AGMX 1 antibody; AGMX1 antibody; AT antibody; ATK antibody; B cell progenitor kinase antibody; B-cell progenitor kinase antibody; BPK antibody; Bruton agammaglobulinemia tyrosine kinase antibody; Bruton tyrosine kinase antibody; Bruton鈥檚 Tyrosine Kinase antibody; Btk antibody; BTK_HUMAN antibody; dominant-negative kinase-deficient Brutons tyrosine kinase antibody; IMD 1 antibody; IMD1 antibody; MGC126261 antibody; MGC126262 antibody; OTTHUMP00000063593 antibody; PSCTK 1 antibody; PSCTK1 antibody; truncated Bruton agammaglobulinemia tyrosine kinase antibody; Tyrosine protein kinase BTK antibody; Tyrosine-protein kinase BTK antibody; tyrosine-protein kinase BTK isoform (lacking exon 14 antibody; XLA antibody
-
宿主：Rabbit
-
反應種屬：Human,Mouse,Rat
-
免疫原：Synthesized peptide derived from Human Btk around the phosphorylation site of Y223.
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：Non-conjugated
-
抗體亞型：IgG
-
純化方式：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
-
產品提供形式：Liquid
-
應用范圍：WB, ELISA
-
推薦稀釋比：
Application Recommended Dilution WB 1:500-1:2000 ELISA 1:40000 -
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis.
-
基因功能參考文獻：
- Btk acts in the TLR7/8 pathway and mediates Ser-536 phosphorylation of p65 RelA and subsequent nuclear entry in primary human macrophages. PMID: 29567473
- Study shows that high BTK expression predicts poor outcome in patients with glioma. Its overexpression is required for EGFR-induced NF-kappaB activation. PMID: 28946903
- The Btk-dependent PIP5K1gamma lipid kinase activation by Fas counteracts FasL-induced cell death. PMID: 28879546
- Study utilized bone biopsies from patients with metastatic multiple myeloma and demonstrated that tyrosine phosphorylation by Bruton kinase may be a key disease event: Bruton kinase remained translocated to the membrane; upregulation of transcripts of several factors like activins A; increased expression of numerous cytokines that support osteolytic activity. PMID: 29480835
- BTK-inhibitor ibrutinib and FK866 resulted in a significant and synergistic anti-Waldenstrom macroglobulinemia cell death, regardless of MYD88 and CXCR4 mutational status. PMID: 27287071
- Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. PMID: 26961147
- these data show that BTK is a critical NLRP3 inflammasome regulator PMID: 28216434
- Resistant BTK mutants reconstituted B cell receptor-triggered chemokine secretion in the presence of corresponding inhibitors, demonstrating that BTK activity is connected with cell-intrinsic functions of malignant B cells with importance for their dialogue with the micro-environment. PMID: 28573668
- Bone marrow mesenchymal stem cells could increase myeloma stemness via activation of the BTK signal pathway. PMID: 28273548
- the results show that the interaction between BTK and ANKRD54 is highly selective, since it was also identified in a screen using human SH3-domainome. A novel finding is that BTK not only binds to ANKRD54, but stands out as the preferred interactor, being highly dominant over all other human SH3-domains. PMID: 28369144
- BTK, via p65BTK expression, is a novel and powerful oncogene acting downstream of the RAS/MAPK pathway and suggest that its targeting may be a promising therapeutic approach. PMID: 26804170
- We conclude that despite being involved in oncogenic signals in blood malignancies, BTK has antineoplastic properties in other contexts, such as the enhancement of p53's tumor suppressor responses PMID: 27630139
- Inhibition of Btk by inhalation of aerosolized RN983 may be effective as a stand-alone asthma therapy. PMID: 27111445
- LMP2A signaling results in STAT3 phosphorylation in B cells through a PI3K/BTK-dependent pathway. PMID: 27792904
- Case Report: Btk mutation responsible for X-Linked agammaglobulinemia manifesting as Pseudomonas aeruginosa liver abscess. PMID: 28398200
- this review describes contributions of BTK to immune tolerance, including studies testing BTK-inhibitors for treatment of autoimmune diseases PMID: 26864273
- The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin. PMID: 28422989
- report that BTK is expressed by murine and human MDSCs, and that ibrutinib is able to inhibit BTK phosphorylation in these cells PMID: 26880800
- Novel BTK mutations have been described in a large cohort of North African patients with X-Linked agammagobulinemia. PMID: 26931785
- mutational analysis in cohort of Iranian patients with congenital agammaglobulinemia PMID: 26910880
- We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. PMID: 26715645
- Data show that Bruton tyrosine kinase (BTK)inhibitor Ibrutinib augments MALT lymphoma associated translocation protein (MALT1) inhibition by S-Mepazine in CD79 antigen mutant activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL). PMID: 26540570
- BTK-C is a survival factor in prostate cancer cells. PMID: 26383180
- BTK RNA interference inhibits proliferation of FLT3-ITD acute myeloid leukemia cells. PMID: 26292723
- Activates PKC independent of BTK. PMID: 26089373
- study investigated all single-nucleotide substitution-caused amino acid variations in the kinase domain of Bruton tyrosine kinase; most disease-causing variations affect conserved and buried residues disturbing protein stability; sixty-seven percent of variations are predicted to be harmful PMID: 25777788
- Data show that Bruton tyrosine kinase (Btk) inhibitor PLS-123 suggested a new direction to pharmacologically modulate Btk function and develop novel therapeutic drug for B-cell lymphoma treatment. PMID: 25944695
- FcgammaRIIB requires Btk and p38 MAPK to mediate antigen-independent inhibition in human B cells. PMID: 26475492
- We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer. PMID: 26036311
- Letter: report BTK inhibitor ibrutinib induced panniculitis in lymphoid leukemia patients. PMID: 26182170
- study indicates that BTK is essential for NLRP3 inflammasome activation and could be a potent therapeutic target in ischaemic stroke PMID: 26059659
- Data indicate that the X linked agammaglobulinemia (XLA) diagnosis was confirmed for six patients with six different mutations. PMID: 26387629
- The immunoglobulin tail tyrosine motif in the cytoplasmic segments of membrane-bound IgGs acts as the principle signal amplifier by incorporating a Grb2-Btk signaling. PMID: 25413232
- Btk not only plays a fundamental role in the regulation of BCR signalling, but may also mediate crosstalk with cytokine signalling pathways through regulation of IL-21-induced phosphorylation of STAT1 in the nuclei of human B cells. PMID: 25724205
- The BTK missense mutation resulted in B cells with reduced BTK and high IgM expression. PMID: 25589397
- BTK is involved in determining proliferative, quiescent or metastatic phenotypes of myeloma cells. PMID: 25083818
- report of a case in a male with variant form of X-linked agammaglobulinemia (XLA) with partial B cell function that results from a missense mutation (c.1117C > G) in exon 13 of the BTK gene; four female carriers were found in the family PMID: 25316352
- miR-155 affects chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib PMID: 25486872
- BTK is a positive regulator of myeloma stemness PMID: 25589346
- Cysteine 481 to serine BTK mutation confers ibrutinib resistance of chronic lymphocytic leukemia cells. PMID: 25189416
- FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation PMID: 25605370
- Data indicate that dual inhibition of Brutons tyrosine kinase (BTK) and mTOR serine-threonine kinases as a potential treatment for ABC-subtype diffuse large B cell lymphoma. PMID: 24970801
- Docking and physicochemical studies indicated that BTK was involved in close contact with Tyr86 and Tyr106 of MAL, whereas PKCdelta may phosphorylate Tyr106 only. PMID: 24840642
- X-linked agammaglobulinemia is reported in two siblings with a novel mutation in the BTK gene. They presented with polyarticular juvenile idiopathic arthritis. PMID: 25757060
- Data indicate RN486 as potent and selective Bruton's tyrosine kinase (BTK) inhibitor and potential treatments for Rheumatoid arthritis. PMID: 24712864
- we report the pattern of expression of Btk in a large collection of different types of lymphoma. PMID: 25433814
- Data indicate that ibrutinib-resistant Bruton tyrosine kinase (BTK) mutation is one of the genetic causes of ibrutinib resistance in chronic lymphocytic leukemia (CLL). PMID: 25498455
- Unfolded protein response activation following surface immunoglobulin M stimulation in vitro is dependent on the activity of BTK and SYK. PMID: 25170122
- We observed that Nef interacts with the Tec family members Bmx, Btk, and Itk but not Tec or Txk. PMID: 24722985
- These results suggest that the function of BTK warrants further investigation, and BTK expression might be used as a prognostic indicator for patients with MM. PMID: 23581641
顯示更多
收起更多
-
相關疾病：X-linked agammaglobulinemia (XLA); X-linked hypogammaglobulinemia and isolated growth hormone deficiency (XLA-IGHD)
-
亞細胞定位：Cytoplasm. Cell membrane; Peripheral membrane protein. Nucleus. Note=In steady state, BTK is predominantly cytosolic. Following B-cell receptor (BCR) engagement by antigen, translocates to the plasma membrane through its PH domain. Plasma membrane localization is a critical step in the activation of BTK. A fraction of BTK also shuttles between the nucleus and the cytoplasm, and nuclear export is mediated by the nuclear export receptor CRM1.
-
蛋白家族：Protein kinase superfamily, Tyr protein kinase family, TEC subfamily
-
組織特異性：Predominantly expressed in B-lymphocytes.
-
數據庫鏈接：
Most popular with customers
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-
